Profil Science Report 2014

Home , Aleglitazar

Profil Science Report

2014

Content

Profil Science Report 2014 ...... 1

Metrics ...... 3

Scientific Publications ...... 5

Original Articles ...... 5

Reviews ...... 11

Letters / Comments ...... 14

Book ...... 15

Scientific Congress Presentations ...... 16

Oral Presentations ...... 16

Poster Presentations ...... 20

Advanced Training Courses ...... 26

Science Sessions ...... 26

Trainings with External Participants ...... 26

Granted Research Projects ...... 27

Metrics M

Scientific Publications

Original Articles

1. Ruan, Y., Benesch, C., Zijlstra, E., Hovorka, R. Modelling glucose kinetics during euglycaemic clamp following administration of rapid acting insulin analogue. Computer Methods and Programs in Biomedicine. In press, 2014 IF(2013): 2.472

2. Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C.B., Flint, A. Semaglutide, a once-weekly human GLP-1 analog does not reduce the bioavailability of the combined oral contraceptive ethinylestradiol/levonogestrel. J. Clin. Pharmacol. DOI: 10.1002/jcph.443, 2014 IF(2013): 2.472

3. Becker, R.H., Nowotny, I., Teichert, L., Bergmann, K., Kapitza, C. Low within- and between-day variability in exposure to new insulin glargine 300 U∙mL-1. Diabetes Obes. Metab. doi: 10.1111/dom.12416, 2014 [Epub ahead of print] IF(2013): 5.456

4. Sha, S., Polidori, D., Farrell, K., Ghosh, A., Natarajan, J., Vaccaro, N., Pinheiro, J., Rothenberg, P., Plum-Mörschel, L. Pharmacodynamic Differences Between Canagliflozin and Dapagliflozin: Results of a Randomized, Double-Blind, Crossover Study. Diabetes Obes. Metab. doi: 10.1111/dom.12418, 2014 [Epub ahead of print] IF(2013): 5.456

5. Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., Becker, R.H. Single-dose new insulin glargine 300 U∙mL-1 provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes. Metab. doi: 10.1111/dom.12415, 2014 [Epub ahead of print] IF(2013): 5.456

6. Leelarathna, L., Dellweg, S., Mader, J.K., Barnard, K., Benesch, C., Ellmerer, M., Heinemann, L., Kojzar, H., Thabit, H., Wilinska, M.E., Wysocki, T., Pieber, T.R., Arnolds, S., Evans, M.L., Hovorka, R. for the AP@home consortium. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol. BMJ Open 4(9):e006075, 2014 IF(2013): 2.063

7. Becker, R.H., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., Heise, T. New insulin glargine 300 units·mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units·mL-1. Diabetes Care. PII: DC_140006, 2014 [Epub ahead of print] IF(2013): 8.570

8. Sha, S., Devineni, D., Ghosh, A., Polidori, D., Hompesch, M., Arnolds, S., Morrow, L., Spitzer, H., Demarest K, Rothenberg P. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 9(9): e110069, 2014 IF(2013): 3.534

9. Nosek, L., Coester, H.V., Roepstorff, C., Thomsen, H.F., Kristensen, N.R., Haahr, H., Heise T. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. Clin. Drug. Investig. 34(9): 673-679, 2014 IF(2013): 1.704

10. Rucci, N., Capulli, M., Piperni, S.G., Cappariello, A., Lau, P., Frings-Meuthen, P., Heer, M., Teti, A. Lipocalin 2: a new mechanoresponding gene regulating bone homeostasis. J. Bone Miner. Res. doi: 10.1002/jbmr.2341, 2014 [Epub ahead of print] IF(2013): 6.589

11. Morgan, J.L., Heer, M., Hargens, A.R., Macias, B.R., Hudson, E.K., Shackelford, L.C., Zwart, S.R., Smith, S.M. Sex-specific responses of bone metabolism and renal stone risk during bed rest. Physiol. Rep. 2(8). PII: e12119, 2014 IF(2013): -

12. Dungan, K.M., Povedano, S.T., Forst, T., González, J.G., Atisso, C., Sealls, W., Fahrbach J.L. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 84(9951):1349-1357, 2014 IF(2013): 39.207

13. Leelarathna, L., Dellweg, S., Mader, J.K., Allen, J.M., Benesch, C., Doll, W., Ellmerer, M., Hartnell, S., Heinemann, L., Kojzar, H., Michalewski, L., Nodale, M., Thabit, H., Wilinska M.E., Pieber, T.R., Arnolds, S., Evans, M.L., Hovorka, R. for the AP@home Consortium. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three- center randomized crossover study. Diabetes Care. 37(7): 1931-1937, 2014 IF(2013): 8.570

14. Pfützner, A., Dissel, S., Forkel, C., Grenningloh, M., Bitton, G., Nagar, R., Forst, T. Standardized modulation of the injection site allows for insulin dose reduction without deterioration of metabolic control. Curr. Med. Res. Opin. 30(10): 2001-2008, 2014 IF(2013): 2.372

15. Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S.S., Sica, D., Rothenberg, P., Plum-Mörschel, L. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 16(11): 1087-1095, 2014 IF(2013): 5.456

16. Pfützner, A., Forst, T., Niemeyer, M., Bailey, T. Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals. Expert. Opin. Drug Deliv. 11(9): 1381-1389, 2014 IF(2013): 4.116

17. Heise, T., Nosek, L., Roepstorff, C., Chenji, S., Klein, O., Haahr H. Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther. 5(1): 255-265, 2014 IF(2013): -

18. Forst, T., Weber, M.M., Mitry, M., Müller, L., Forst, S., Tanis, M., Pfützner, A., Michelson, G. Retinal microcirculation in type 1 diabetic patients with and without peripheral sensory neuropathy. J. Diabetes Sci. Technol. 8(2): 356-361, 2014 IF(2013): -

19. Beyer, U., Wyss, T., Robin, F., Heinemann, L. Glucose measurement by affinity sensor and pulsed measurements of fluidic resistances: proof of principle. J. Diabetes Sci. Technol. 8(1): 100-108, 2014 IF(2013): -

20. Smith, S.M., Castaneda-Sceppa, C., O'Brien, K.O., Abrams, S.A., Gillman, P., Brooks, N.E., Cloutier, G.J., Heer, M., Zwart, S.R., Wastney, M.E. Calcium kinetics during bed rest with artificial gravity and exercise countermeasures. Osteoporos. Int. 25(9): 2237-2244, 2014 IF(2013): 4.165

21. Heise, T., Morrow, L., Hompesch, M., Häring, H.U., Kapitza, C., Abt, M., Ramsauer, M., Magnone, M.C., Fuerst-Recktenwald, S. Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. Diabetes Obes. Metab. 16(11): 1070-1077, 2014 IF(2013): 5.456

22. Heise, T., Larbig, M., Patel, S., Seck, T., Hehnke, U., Woerle, H.J., Dugi, K. The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes. Diabetes Obes. Metab. 16(10): 1036-1039, 2014 IF(2013): 5.456

23. Skrivanek, Z., Gaydos, B.L., Chien, J.Y., Geiger, M.J., Heathman, M.A., Berry, S., Anderson, J.H., Forst, T., Milicevic, Z., Berry, D. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes. Metab. 16(8): 748-56, 2014 IF(2013): 5.456

24. Heer, M., Baecker, N., Wnendt, S., Fischer, A., Biolo, G., Frings-Meuthen, P. How fast is recovery of impaired glucose tolerance after 21-day bed rest (NUC study) in healthy adults? Scientific World Journal. DOI: 10.1155/2014/803083, eCollection 2014. IF(2013): -

25. Heise, T., Nosek, L., Dellweg, S., Zijlstra, E., Præstmark, K.A., Kildegaard, J., Nielsen, G., Sparre. T. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes. Metab. 16(10): 971-976, 2014 IF(2013): 5.456

26. Schliess, F., Hoehme, S., Henkel, S.G., Ghallab, A., Driesch, D., Böttger, J., Guthke, R., Pfaff, M., Hengstler, J.G., Gebhardt, R., Häussinger, D., Drasdo, D., Zellmer, S. Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology 60(6): 2040-2051, 2014 IF(2013): 11.19

27. Forst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., Stein, P. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes. Metab. 16(5): 467-477, 2014 IF(2013): 5.456

28. Seino, Y., Takami, A., Boka, G., Niemoeller, E., Raccah, D., PDY6797 investigators (D'Emden, M., Lowy, A., Forst, T., Hanefeld, M., Wagner, F., Fuyuko, K., Hayakawa, H., Imamura, A., Kanada, S., Jinnouchi, H., Kasahara, H., Kawa, I., Maeda, S., Matsubayashi, S., Morita, H., Nagashima, H., Nakano, K., Onde, H., Saito, Y., Satake, K., Shoji, S., Toh, Y., Tokoo, M., Wakida, Y., Yano, S., Yoshida, H., Burger, F., Ellis, G., Malan, J., Bak, A., Reintke, H., Rongen, G.) Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. Diabetes Obes. Metab. 16(8): 739-747, 2014 IF(2013): 5.456

29. Becker, R.H., Stechl, J., Msihid, J., Kapitza, C. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes - a study in both people with type 2 diabetes and healthy subjects. Diabetes Obes. Metab. 16(9): 793-800. IF(2013): 5.456

30. Smith, S.M., Zwart, S.R., Heer, M., Hudson, E.K., Shackelford, L., Morgan, J.L. Men and women in space: bone loss and kidney stone risk after long-duration spaceflight. J. Bone Miner. Res. 29(7): 1639-45, 2014 IF(2013): 6.589

31. Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U.C., Woerle, H.J. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 24(2): 499-508, 2014 IF(2013): 13.765

32. Forst, T., Anastassiadis, E., Diessel, S., Löffler, A., Pfützner, A. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment. Diabetes Metab. Res. Rev. 30(7): 582-589, 2014 IF(2013): 5.456

33. Nauck, M.A., Haastert, B., Trautner, C., Müller, U.A., Heinemann, L. for the Clinical Trials Study Group of the German Association for the Study of Diabetes. A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment. Diabetologia 57(5): 868-577, 2014 IF(2013): 6.880

34. Pfützner, A., Hermanns, N., Funke, K., Forst, T., Behnke, T., Bitton, G., Nagar, R., Raz, I., Haak, T. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus. Curr Med Res Opin. 30(5): 753-760. IF(2013): 2.372

35. Stirban, A., Nandrean, S., Götting, C., Stratmann, B., Tschoepe, D. Effects of n-3 polyunsaturated fatty acids (PUFAs) on circulating adiponectin and leptin in subjects with type 2 diabetes mellitus. Horm Metab Res. 46(7): 490-492, 2014 IF(2013): 2.083

36. Karababa, A., Görg, B., Schliess, F., Häussinger, D. O-GlcNAcylation as a novel ammonia-induced posttranslational protein modification in cultured rat astrocytes. Metab. Brain Dis. 29(4): 975-82, 2014 IF(2013): 2.398

37. Pfützner, A., Hengesbach, C., Demircik, F., Schipper, C., Forst, T., Musholt, P.B. Performance of blood glucose meters in compliance with current and future clinical ISO15197 accuracy criteria. Curr. Med. Res. Opin. 30(2): 185-90, 2014 IF(2013): 2.372

38. Sinha, V.P., Howey, D.C., Choi, S.L., Mace, K.F., Heise, T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 16(4): 344-350, 2014 IF(2013): 5.456

Reviews

39. DeVries, J.H., Gough, S.C., Kiljanski, J., Heinemann, L. Common standards of basal insulin titration in type 2 diabetes. Diabetes Obes. Metab. DOI: 10.1111/dom.12410, 2014 [Epub ahead of print] IF(2013): 5.456

40. Heinemann, L. Google CGM: does this product already helps patients with diabetes? Dtsch. Med. Wochenschr. 139(38): 1898, 2014 IF(2013): 0.550

41. Stirban, A. Microvascular dysfunction in the context of diabetic neuropathy. Curr. Diab. Rep. 14(11): 541, 2014 IF(2013): 3.377

42. Haahr, H., Heise, T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin. Pharmacokinet. 53(9): 787-800, 2014 IF(2013): 5.486

43. Heinemann, L., Hirsch, L., Hovorka, R. Lipohypertrophy and the artificial pancreas: is this an issue? J. Diabetes Sci. Technol. 8(5): 915-917, 2014 IF(2013): -

44. Smith, S.M., Abrams, S.A., Davis-Street, J.E., Heer, M., O'Brien, K.O., Wastney, M.E., Zwart, S.R. Fifty years of human space travel: implications for bone and calcium research. Annu. Rev. Nutr. 34: 377-400, 2014 IF(2013): 10.459

45. Zijlstra, E., Heinemann, L., Plum-Mörschel, L. Oral insulin reloaded: a structured approach. J. Diabetes Sci. Technol. 8(3): 458-465, 2014 IF(2013): -

46. Lodwig, V., Kulzer, B., Schnell, O., Heinemann, L. What are the next steps in continuous glucose monitoring? J. Diabetes Sci. Technol. 8(2): 397-402, 2014 IF(2013): -

47. Lodwig, V., Kulzer, B., Schnell, O., Heinemann L. Current trends in continuous glucose monitoring. J. Diabetes Sci. Technol. 8(2): 390-396, 2014 IF(2013): -

48. Heinemann. L., Walsh, J., Roberts, R. We need more research and better designs for insulin infusion sets. J. Diabetes Sci. Technol. 8(2): 199-202, 2014 IF(2013): -

49. Walsh, J., Roberts, R., Heinemann, L. Confusion regarding duration of insulin action: a potential source for major insulin dose errors by bolus calculators. J. Diabetes Sci. Technol. 8(1): 170-178, 2014 IF(2013): -

50. Forst, T., Bramlage, P. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert. Opin. Pharmacother. 15(9): 1299-313, 2014 IF(2013): 3.085

51. Stirban, A., Gawlowski, T., Roden, M. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol. Metab. 3(2): 94-108, 2013, eCollection 2014 IF(2013): -

52. Heer. M., Egert, S. Nutrients other than carbohydrates: their effects on glucose homeostasis in humans. Diabetes Metab. Res. Rev. DOI: 10.1002/dmrr.2533, 2014 [Epub ahead of print] IF(2013): 3.593

53. Heinemann, L., Hompesch, M. Biosimilar insulins: basic considerations. J. Diabetes Sci. Technol. 8(1): 6-13, 2014 IF(2013): -

54. Schnell, O., Hinzmann, R., Kulzer, B., Freckmann, G., Erbach, M., Lodwig, V., Heinemann, L. Assessing the analytical performance of systems for self-monitoring of blood glucose: concepts of performance evaluation and definition of metrological key terms. J Diabetes Sci. Technol. 7(6): 1585-94, 2013 IF(2013): -

55. Heise, T., Meneghini, L.F. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr. Pract. 20(1): 75-83, 2014 IF(2013): 2.490

56. Stirban A., Heinemann, L. Skin autofluorescence: a non-invasive method for assessing cardiovascular risk and risk of diabetes. European Endocrinology 10:106-110, 2014 IF(2013): -

Letters / Comments

57. Dolinar, R.O., Edelman, S., Heinemann, L., Home, P., Goyal, S., Polonsky, W.H., Schellekens, H. Impact of biosimilar insulins on clinical practice: meeting report. J. Diabetes. Sci. Technol. 8(1): 179-185, 2014 IF(2013): -

58. Stirban, A. Measurement of lens autofluorescence for diabetes screening. J. Diabetes Sci. Technol. 2014 8(1): 50-53, 2014 IF(2013): -

59. Heinemann, L. EASD Diabetes Technology Meeting: medical associations are on track. J. Diabetes Sci Technol. PII:1932296814534630, 2014 [Epub ahead of print] IF(2013): -

60. Roberts, R., Walsh, J., Heinemann, L. Help! Someone is beeping … J. Diabetes Sci. Technol. PII: 1932296814532882, 2014 [Epub ahead of print] IF(2013): -

61. Heinemann, L. Insulin pens and new ways of insulin delivery. Diabetes Technol. Ther. 16 Suppl 1: S44-55, 2014 IF(2013): 2.293

62. Stirban, A., Tschoepe, D. Comment on "Advanced glycation endproducts in food and their effects on health" by Poulsen et al. (2013) Food and Chemical Toxicology 60, 10-37. Food Chem. Toxicol. 64: 411, 2014 IF(2013): 3.210

63. Heinemann, L., DeVries, J.H. Evidence for continuous glucose monitoring: sufficient for reimbursement? Diabet. Med. 31(2): 122-125, 2014 IF(2013): 3.064

64. Ziegler, R., Schnell, O. Kulzer, B., Heinemann, L. Freedom of science: can industry influence what scientists publish? European Endocrinology 10: 10-13, 2014 IF(2013): -

Book

65. Krentz, A., Heinemann, L., Hompesch, M. (eds.) Translational research methods for diabetes, obesity and cardiometabolic drug development: a focus on early stage clinical studies. DOI 10.1007/978-1-4920-0_1, Springer-Verlag London, 2015

Scientific Congress Presentations

Oral Presentations

DDG Diabetes Herbsttagung / Adipositas Jahrestagung Leipzig, Germany, 21 – 22 November 2014

66. Forst, T. Insuline und GLP-1 Rezeptorantagonisten am Horizont: was können wir erwarten?

42th Jahrestagung der Österreichischen Diabetesgesellschaft, Salzburg, Austria 20 – 22 November 2014

67. Forst, T. Nebenwirkungen – wer fürchtet sich vor Sulfonylharnstoffen?

53rd Annual European Society for Paediatric Endocrinology (ESPE) Meeting, Dublin, Ireland, 18 – 20 November 2014

68. Welters, A., Marquard, J., Otter, S., Stirban, A., Eglinger, J., Herebian, D., Kletke, O., Klemen, M.S., Stozer, A., Wnendt, S., Piemonti, L., Köhler, M., Schliess, F., Rupnik, M.S., Heise, T., Berggren, P.O., Klöcker, N., Mayatepek, E., Eberhard, D., Kragl, M., Lammert, E., Meissner, T. Pancreatic N-methyl-D-asparte receptors as novel drug targets for the treatments of diabetes mellitus.

BIT’s 12th Annual Congress of International Drug Discovery Science & Technology (IDDST) 2014, Suzhou, China, 18 – 20 November 2014

69. Marquard, J., Meissner, T., Welters, A., Otter, S., Stirban, A., Schliess, F., Heise, T., Herebian, D., Mayatepek, E., Lammert, E. Effect of N-Methyl-D-Aspartate receptor antagonist dextromethorphan on glycemic control and islet-cell protection in type 2 diabetes.

Border Sessions International Technology Festival, The Hague, The Netherlands, 12 – 13 November 2014

70. Schliess, F. E-healing of diabetes: the artificial pancreas for at home.

Jahrestagung der Schweizerischen Gesellschaft für Endokrinologie und Diabetologie, Bern, Switzerland, 12 – 13 November 2014

71. Forst, T. The two week fasting glucose as a predictor of the response to once weekly dulaglutide 1.5.

Forum Diabetes, München, Germany, 8 November 2014

72. Forst, T. Update orale Antidiabetika. SGLT-2 Hemmer – wo stehen wir heute?

73. Forst, T. New perspectives in the treatment of diabetes.

14th Annual Diabetes Technology Meeting, Bethesda, Maryland, USA, 6 – 8 November 2014

74. Heinemann, L. Better lancing technology.

75. Heinemann, L. Short acting and long acting insulins in the pipeline.

Middle East and South Africa Scientific Exchange, Dubai, Vereinigte Arabische Emirate, 30 – 31 October 2014

76. Forst, T. Novel tharapies and mechanisms for the treatment of diabetes.

77. Forst, T. Risk-benefit of incretin-based therapies.

Gulf Chapter of AACE Congress Abu Dhabi, Vereinigte Arabische Emirate, 23 – 24 October 2014

78. Forst T. Update on GLP receptor antagonists: past, present and future.

50th EASD Annual Meeting, Vienna, Austria, 15 – 19 September

79. Toefe Povedano, S., Dungan, K.M., Forst, T., González, J.G., Atisso, C., Sealls, W., Fahrbach, J.L. Efficacy and safety of once weekly dulaglutide versus once daily liraglutide in type 2 diabetes (AWARD-6). Diabetologia 57(Suppl 1): A40, 2014

80. Menge, B.A., Kapitza, C., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.V., Forst T., Meier, J.J. Impact of baseline gastric emtying on effects on lixisenatide and liraglutide in type 2 diabetes mellitus as add on to insuline glargine. Diabetologia 57(Suppl 1): A75, 2014

81. Heise, T., Haahr, H.L., Jensen, L., Erichsen, L., Hompesch, M. Faster-acting insulin aspart improves postprandial glycemia versus insulin aspart in patients with type 1 diabetes mellitus. Diabetologia 57(Suppl 1): A120, 2014

ADA 74th Scientific Sessions, San Francisco, CA, 13-17 June 2014

82. Heise, T., Haahr, H.L., Jensen, L., Erichsen, L., Hompesch, M. Faster-acting insulin aspart improves postprandial glycemia vs. insulin aspart in patietns with type 1 diabetes mellitus (T1DM). Diabetes 63(Suppl 1): 129-OR

83. Leelarathna, L., Dellweg, S., Mader, J.K., Allen, J.M., Benesch, C., Doll, W., Ellmerer, M., Hartnell, S., Heinemann, L., Kojzar, H., Michalewski, L., Nodale, M., Thabit, H., Wilinska, M.E., Pieber, T.R., Arnolds, S., Evans, M.L., Hovorka, R. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three centre randomised crossover study. Diabetes 63(Suppl 1): 235-OR

84. Sha, S., Polidori D., Heise, T., Natarajan, J., Farrell, K., Wang, S.S., Sica, D., Rothenberg, P., Plum-Mörschel, L. Temporal changes in urinary glucose excretion (UGE), urine volume (UV), and plasma volume (PV) in subjects with type 2 diabetes mellitus (T2DM) treated with canagliflozin (CANA). Diabetes 63(Suppl 1): 263-OR

Keystone Symposium: Emerging Concepts and Targets in Islet Biology (D3-2014), Keystone, Colorado, USA, 6 – 11 April 2014

85. Schliess, F. The NMDA receptor antagonist dextromethorphan reduces OGTT-related glycaemia in patients with T2DM: a randomized, double blind, placebo-controlled, fourfold cross-over clinical trial.

35th Annual International Gravitational Physiology Meeting & 1st Aging in Space Symposium, Waterloo, Canada, 16 – 20 June 2014

86. Heer, M. Nutrition physiology in aging, bed rest and space flight.

87. Graf, S., Baecker, N., Buehlmeier, J., Fischer, A., Smith, S.M., Heer, M., Liphardt, A., Boyd, S.K. Effects of resistive vibration exercise combined with whey protein and KHCO3 on bone turnover markers in head‐down tilt bed rest (MTBR‐MNX Study).

88. Liphardt, A.M., Mündermann, A., Koo, S., Andriacchi, T.P., Achtzehn, S., Heer, M., Mester, J. Relevance of immobility for serum levels of biomarkers for cartilage health.

49th Jahrestagung der Deutschen Diabetes Gesellschaft, Berlin, Germany, 28 – 31 Mai 2014

89. Heise, T. Insulin degludec – ein neuer Standard in der Insulintherapie.

90. Heinemann, L. Duration of insulin action: das unbekannte Wesen.

50th Workshop for Pediatric Research, Göttingen, Germany. 20 – 21 March 2014

91. Marquard, J., Otter, S., Welters, A., Herebian, D., Demir, F., Schroeter, A., Kletke, O., Kragl, M., Eberhard, D., Bartosinska, B., Klemen, M.S., Stozer, A., Köhler, M., Stirban, A., Schliess, F., Heise, T., Wnendt, S., Rupnik, M.S., Berggren, P.O., Klöcker, N., Meissner, T., Mayatepek, E., Lammert, E. NMDA receptor dependent anti-diabetic effects. Molecular and Cellular Pediatrics 1(Suppl 1): A26, 2014

Poster Presentations

10th IDF-WPR and 6th AASD Scientific Meeting, Singapore, 21 – 24 November 2014

92. Heise, T., Nosek, L., Coester, H.V., Klein, O., Roepstorff, C., Svendsen, A.L., Haahr, H. Insulin Degludec/Insulin Aspart (IDegAsp) Produces a Dose Proportional Glucose Lowering Effect in Subjects with Type 1 Diabetes. PO242

14th Annual Diabetes Technology Meeting, Bethesda, Maryland, USA, 6 -– 8 November 2014

93. Zijlstra, E., Heinemann, L., Fischer, A., Kapitza, C. A new 3-step clamp method for the evaluation of blood glucose meters. J. Diabetes. Sci. Technol. In press

94. Benesch, C., Haensler, J., Heise, T. Improved automated glucose clamps using algorithm variations with the ClampArt Device. J. Diabetes Sci. Technol. In press

Gulf Chapter of AACE Congress Abu Dhabi, Vereinigte Arabische Emirate, 23 – 24 October 2014

95. Forst, T., Tofé, P.S., Dungan, K.M., González, J.G., Atisso, C., Sealls, W., Fahrbach, J.L. Efficacy and safety of once-weekly dulaglutide versus once-daily liraglutide in type 2 diabetes (AWARD-6). PO23, 2014

50th EASD Annual Meeting, Vienna, Austria, 15 – 19 September

96. Meier, J.J., Rosenstock, J., Hincelin-Mèry, A., Roy-Duval, C., Delfolie, A., Coester, H.V., Forst, T., Kapitza, C. Effect of lixisenatide vs liraglutide on glycaemic control, gastric emptying and safety parameters in optimised insulin glargine type 2 diabetes mellitus ± metformin. Diabetologia 57(Suppl 1): A926, 2014

97. Hoevelmann, U., Alluis, B., Meiffren, G., Ranson, A., Soula, O., Soula, G., Soula, R., Kronshage, B., Nosek, L., Famulla, S., Heise, T. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of BioChaperone Combo (BC Combo), the first fixed combination of glargine and lispro, in type 1 diabetes (T1DM). Diabetologia 57(Suppl 1): A932, 2014

98. Andersen, G., Alluis, B., Meiffren, G., Ranson, A., Soula, O., Soula, G., Soula, R., Fischer, A., Nosek, L., Schliess F., Heise, T. The ultra-rapid BioChaperone insulin lispro shows a faster onset of action and stronger early metabolic effect than insulin lispro alone. Diabetologia 57(Suppl 1): A934, 2014

99. Haahr, H., Hövelmann, U., Brønsted, L., Adrian, C.L., Nosek, L., Heise, T. Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart in patients with type 1 diabetes mellitus. Diabetologia 57(Suppl 1): A936, 2014

100. Arnolds, S., Heckermann, S., Sawicki, P.T. Spectrum of diabetes research does not reflect patients’ scientific preferences. Diabetologia 57(Suppl 1): A1034, 2014

101. Forst, T., Gough, S., Grunberger, G., Pechtner, V., Shaginian, R., Wang H., Fernandez. L. The 2 week fasting glucose as a predictor of response to once weekly dulaglutide 1.5 mg. Diabetologia 57(Suppl 1): A827, 2014

102. Leelarathna, L., Hood, T., Elleri, D., Allen, J.M., Lubina-Solomon, A., Mader, J., Benesch, C., Stadler, M., Pieber, T.R., Arnolds, S., Heller, S.R., Amiel, S.A., Dunger, D.B., Evans, M.L., Hovorka, R. Diabetologia 57(Suppl 1): A989, 2014

103. Strotmann, H.J., Goetze, D., Koch, C., Forst, T. Vildagliptin versus insulin as add on therapy to glimepiride in type 2 diabetes mellitus: results from a randomised controlled study. Diabetologia 57(Suppl 1): A895, 2014

104. Becker, R.H., Nowotny, I., Teichert, L., Bergmann, K., Kapitza, C. Low within- and between-day variability in exposure to new insulin glargine 300 U∙ml-1. Diabetologia 57(Suppl 1): A953, 2014

105. Kapitza, C., Bode, B.W., Ingwersen, S.H., Jacobsen, L.V., Poulsen, P. Preserved pharmacokinetic properties and distinct glycaemic effects of insulin degludec and liraglutide in IDegLira, a fixed ration combination product. Diabetologia 57(Suppl 1): A959

106. Jax, T., Blauw, H., DeVries, J., Heise, T. for the PCDIAB consortium A randomised three-period trial to compare the pharmacodynamics and pahrmacokinetics of different glucagon dosages at different blood glucose levels. Diabetologia 57(Suppl 1): A1011

16th Symposium of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN 2014), London, UK, 10 – 13 September 2014

107. Schliess, F. Diabetic and hepatic encephalopathy: similarities, synergisms and differences. Conference Booklet, Poster Abstract No. 60

ADA 74th Scientific Sessions San Francisco, CA, 13 – 17 June 2014

108. Heise, T., Zhang, X., Quin Lam, E.C., Seger, M.E., Coutant, D., Chua, L., Linnebjerg, H. Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type 1 diabetes mellitus (T1DM). Diabetes 63 (Suppl 1): 891-P, 2014

109. Becker, R.H., Nowotny, I., Teichert, L., Bergmann, K., Kapitza, C. Low within- and between-day variability in exposure to new insulin glargine 300 U∙ml-1. Diabetes 63 (Suppl 1): 892-P, 2014

110. Arnolds, S., Haensler, J., Klein, O., Heinemann, L., Heise, T., Benesch, C. Evaluation of a novel device for fully automated glucose clamps - ClampArt®. Diabetes 63 (Suppl 1): 896-P, 2014

111. Haahr, H., Hoevelmann, U., Brondsted, L., Adrian, C.L., Nosek, L., Heise, T. Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart in patients with type 1 diabetes mellitus (T1DM). Diabetes 63 (Suppl 1): 910-P, 2014

112. Meier, J.J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.V., Forst, T., Kapitza C. Effect of lixisenatide vs. liraglutide on glycemic control, gastric emptying, and safety parameters in optimized insulin glargine T2DM ± metformin. Diabetes 63 (Suppl 1): 1017-P, 2014

113. Jax, T., Blauw, H., Heise, T., DeVries, J.H. for the PCDIAB consortium. A randomized, single center, three-period trial to compare the relative pharmacodynamic (PD) and pharmacokinetic (PK) properties of different glucagon dosages at four different blood glucose (BG) concentration. Diabetes 63 (Suppl 1): 937-P, 2014

114. Leelarathna, L., Dellweg, S., Mader, J.K., Allen, J.M., Benesch, C., Doll, W., Ellmerer, M., Hartnell, S., Heinemann, L., Kojzar, H., Michalewski, L., Nodale, M., Thabit, H., Wilinska, M., Pieber, T.R., Arnolds, S., Evans, M.L., Hovorka R. Factors affecting performance of day and night closed-loop insulin delivery under free living conditions in type 1 diabetes. Diabetes 63 (Suppl 1): 942-P, 2014

115. Pfützner, A., Dissel, S., Raz, I., Haak, T., Bitton, G., Nagar, R., Forst, T. Reduced prandial insulin dose after 3 months with InsuPad results in a similar metabolic control than the original dose at baseline in a meal tolerance test. Diabetes 63 (Suppl 1): 957-P, 2014

116. Jordan, J., Tank, J., Heusser, K., Heise, T., Wanner, C., Heer, M., Macha, S., Mattheus, M., Lund, S.S., Woerle, H.J., Broedl, U. Empagliflozin (EMPA) has no discernable effect on muscle sympathetic nerve activity (MSNA) in patients with type 2 diabetes (T2DM) despite reductions in blood pressure (BP) and weight. Diabetes 63 (Suppl 1): 1030-P, 2014

117. Kazda, C.M., Garhyan, P., Ding, Y., Kelly, R.P., Hardy, T.A., Kapitza C. Patients with T1DM show reduced but clinically significant elevations in response to glucagon injection in the presence of LY2409021. Diabetes 63 (Suppl 1): 1038-P, 2014

118. Stirban, A., Marquard, J., Wnendt, S., Herebian, D., Schliess, F., Heise, T., Lammert, E. Blood glucose lowering effects of dextromethorphan in people with type 2 diabetes mellitus (T2DM). Diabetes 63 (Suppl 1): 1062-P, 2014

119. Usiskin, K., Leiter, L.A., Forst, T., Polidori, D., Xie, J., Sha, S. Effect of canagliflozin (CANA) on liver function tests (LFTs) in patients with type 2 diabetes mellitus. Diabetes 63 (Suppl 1): 1062-P, 2014

120. Stirban, A., Andjelkovic, M., Heise, T., Nosek, L., Fischer, A., Gastaldelli, A., Herz, M. Aleglitazar (ALE) improves insulin sensitivity, glucose control, and lipids in people with type 2 diabetes (T2DM). Diabetes 63 (Suppl 1): 1118-P, 2014

121. Kirchsteiger, H., Freckmann, G., Heinemann, L., Lodwig, L., Schmelzeisen-Redeker, G., Schoemaker, M., del Re, L. Validity of MARD for CGM: Impact of time delay, reference measurement errors and number of reference measurements. Diabetes 63 (Suppl 1): 860-P, 2014

122. Zijlstra, E., Fischer, A., Kapitza, C. Systematic performance evaluation of five blood glucose meters at stable low, normal, and high blood glucose levels. 72-LB

123. Andersen, G., Alluis, B., Meiffren, G., Ranson, A., Soula, O., Soula, G., Soula, R., Fischer, A., Nosek, L., Schliess, F., Heise, T. The ultra-rapid BioChaperone insulin iispro (BC LIS) shows a faster onset of action and stronger early metabolic effect than insulin lispro (LIS). 78-LB

124. Hoevelmann, U., Alluis, B., Meiffren, G., Ranson, A., Soula, O., Soula, G., Soula, R., Kronshage, B., Nosek, L., Famulla, S., Heise, T. Pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of BioChaperone Combo (BC Combo), the first fixed combination of glargine and lispro, in type 1 diabetes. 83-LB

125. Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C.B., Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of oral contraceptives. 2383-PO

49. Jahrestagung der Deutschen Diabetes Gesellschaft, Berlin, Germany, 28. – 31. Mai 2014

126. Lüdemann, J., Bode, B., Heise, T., Pieber, T., Rasmussen, S., Russel-Jones, D. Höhere Raten von bestätigten Hypoglykämien sind mit einer höheren intraindividuellen Variabiliät der Nüchternplasmaglucose bei Typ 1 und Typ 2 Diabetes assoziiert – Ergebnisse einer Metaanalyse. P115

127. Weber, D., Kaltheuner, M., Scheper, N., Hess, G., Faber-Heinemann, G., Heinemann, L. Effekt von Schulung bei gleichzeitiger Umstellung einer medikamentösen Therapie: Daten von 648 Patienten die neu mit GLP-1-Analoga oder DPP-IV Inhibitoren in 38 Diabetes- Schwerpunktpraxen therapiert wurden. P163

Keystone Symposium: Emerging Concepts and Targets in Islet Biology (D3-2014), Keystone, Colorado, USA, 6 – 11 April 2014

128. Otter, S., Marquard, J., Welters, A., Stirban, A., Eglinger, J., Herebian, D., Kletke, O., Klemen, M.S., Stozer, A., Wnendt, S., Piemonti, L., Köhler, M., Schliess, F., Rupnik, M.S., Heise, T., Berggren, P.O., Klöcker, N., Meissner, T., Mayatepek, E., Eberhard, D., Kragl, M., Lammert, E. Regulation of glucose-induced insulin secretion by pancreatic N-methyl-D-aspartate receptors. Conference Booket, Poster Abstract 2030

129. Marquard, J., Otter, S., Welters, A., Stirban, A., Herebian, D., Kletke, O., Skelin, M., Stozer, A., Wnendt, S., Köhler, M., Schliess, F., Heise, T., Rupnik, M.S., Piemonti, L., Berggren, P.O., Klöcker, N., Meissner, T., Mayatepek, E., Eberhard, D., Kragl, M., Lammert, E. Antidiabetic effects of the NMDA receptor antagonist dextromethorphan. Conference Booklet, Poster Abstract 2031

EASD Diabetes Technology Conference, Düsseldorf, Germany, 26 – 27 February 2014.

130. Zijlstra, E., Sparre, T., Nosek, L., Dellweg, S., Praestmark, K.A., Qvist, M., Kjeldsen, B.G., Kildegaard, J., Nielsen, G., Heise T. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh.

Advanced Training Courses

Science Sessions

131. Priv.-Doz. Dr. med. Christoph Schröder

Medizinische Hochschule Hannover, Institut für Klinische Pharmakologie 19. February 2014 SAE-Meldungen in klinischen Studien: Anforderungen nach GCP-V und AMP & praktische Durchführung Trainings with External Participants

132. Profil – Glucose-Clamp-Technique Introduction Course

4 June 2014 Profil, Neuss, Germany Novo Nordisk Bagsvaerd, Denmark

133. Profil – Glucose-Clamp-Technique Introduction Course

22 October 2014 Profil, Neuss, Germany Karl Franzens University of Graz, Austria

134. DuET 2014 Düsseldorf Education on Trials

27 – 28 February 2014 Profil, Neuss, Germany Novo Nordisk, Region Europe A/S

135. DuET 2014 Düsseldorf Education on Trials

6 – 7 November 2014 Profil, Neuss, Germany Novo Nordisk, Region Europe A/S

136. Blockseminar Methoden der Experimentellen Ernährungsforschung

WS 2013/2014 Rheinische Friedrich-Wilhelms-Universität Bonn Profil, Neuss

Granted Research Projects

137. EIT-Health A knowledge and innovation community on healthy living and active ageing. Funded by the European Institute of Innovation and Technology First funding period: 2015 – 2022 http://eit.europa.eu/eit-community/eit-health

138. Competence Center for Biomarker Research in Medicine

COMET K1 Center for Biomarker Research at CBmed Funded by the Austrian Research Promotion Agency First funding period: 2015 – 2019 https://www.ffg.at/

139. Regionales Innovationsnetzwerk Diabetes (RIN Diabetes)

Funding: Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein Westfalen Funding period: 2014 - 2017 http://www.rin-diabetes.de/

140. AP@Home – Bringing the Artificial Pancreas Home

EU Project 7th Framework Programme, contract no. 247138 European Project to Develop Artificial Pancreas for Diabetes Patients February 2010 – October 2014 http://www.apathome.eu/

141. SPIDIMAN – Single-Port Insulin Infusion for Improved Diabetes Management

EU Project 7th Framework Programme, contract no. 305343 European Project to Combine Glucose Monitoring and Insulin Infusion in a Single Needle November 2012 – December 2016 http://www.spidiman.eu/

142. MICROLOOP – Closed-loop glucose control in the hospital

BMBF SME-innovation: Medical Technology Funding Programme, MED-327-060 German Project to Develop a Medical Device for Glucose Control in the Hospital October 2012 – September 2015

143. PCDIAB – Portable bihormonal artificial pancreas

EU Project 7th Framework Programme, contract no. 305654 European Project to bring a portable bihormonal artificial pancreas to the patients’ home September 2012 – August 2015 http://www.PCDIAB.eu/project

144. Auswirkung der Nährstoffzusammensetzung auf den Knochen- und Kohlenhydratstoffwechsel

Toulouse-MTBR-Bettruhe-Experimente PROPEI und Bone Quality, Antarktisstation Concordia Projekt MONU, ISS-Experiment Pro K Rheinische Friedrich-Wilhelms-Universität Bonn, Bundesministerium für Wirtschaft und Energie, Projektträger Raumfahrt im DLR March 2012 – June 2015